Phasebio Pharmaceuticals Reports Q1 Loss Of 23 Cents Per Share

Reuters2022-05-16

PhaseBio Pharmaceuticals Inc :Phasebio Pharmaceuticals Reports First Quarter 2022 Financial Results And Recent Business Highlights.Qtrly Loss Per Share $0.23.Q1 Earnings Per Share View $-0.66 -- Refinitiv Ibes Data.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2235409324?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-05-16 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2235409324","market":"us","top_or_hot":-1,"title":"Phasebio Pharmaceuticals Reports Q1 Loss Of 23 Cents Per Share","media":"Reuters","content":"<html><body><p>PhaseBio Pharmaceuticals Inc <phas.o>:Phasebio Pharmaceuticals Reports First Quarter 2022 Financial Results And Recent Business Highlights.Qtrly  Loss Per Share $0.23.Q1 Earnings Per Share View $-0.66 -- Refinitiv Ibes Data.</phas.o></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Phasebio Pharmaceuticals Reports Q1 Loss Of 23 Cents Per Share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhasebio Pharmaceuticals Reports Q1 Loss Of 23 Cents Per Share\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-16 18:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.trkd.thomsonreuters.com><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PhaseBio Pharmaceuticals Inc :Phasebio Pharmaceuticals Reports First Quarter 2022 Financial Results And Recent Business Highlights.Qtrly  Loss Per Share $0.23.Q1 Earnings Per Share View $-0.66 -- ...</p>\n\n<a href=\"https://www.trkd.thomsonreuters.com\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGEM","symbol_name":"Cullinan Therapeutics","start_time":0,"source_url":"https://www.trkd.thomsonreuters.com","article_id":"2235409324","we_media_id":"1086160438","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2235409324","pubTimestamp":1652695380,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"summary":"PhaseBio Pharmaceuticals Inc :Phasebio Pharmaceuticals Reports First Quarter 2022 Financial Results ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CGEM":"Cullinan Therapeutics","BK4139":"生物科技","BK4023":"应用软件","BK4007":"制药","BK4196":"保健护理服务","LHDX":"Lucira Health, Inc.","ONTF":"ON24, Inc.","APR":"Apria, Inc.","BK4082":"医疗保健设备","LABP":"Landos Biopharma, Inc.","SANA":"Sana Biotechnology, Inc."},"translate_title":"Phasebio Pharmaceuticals报告第一季度每股亏损23美分","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APR":0.9,"CGEM":0.9,"LABP":0.9,"LHDX":0.9,"PHAS":0.9,"SANA":0.9,"ONTF":0.75},"content_text":"PhaseBio Pharmaceuticals Inc :Phasebio Pharmaceuticals Reports First Quarter 2022 Financial Results And Recent Business Highlights.Qtrly  Loss Per Share $0.23.Q1 Earnings Per Share View $-0.66 -- Refinitiv Ibes Data.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2235409324"}